Cost-effectiveness per 1000 pregnant women of vaccination in pregnancy with tetanus–diphtheria–acellular pertussis vaccine
| Variable | Vaccine | No vaccine | Incremental |
|---|---|---|---|
| Cost, $* | |||
| Vaccine | 17 000 | 0 | 17 000 |
| Treatment of pertussis in infant | 404 | 4416 | −4012 |
| Treatment of pertussis and adverse events in woman | 0.1 | 1 | −1 |
| Total | 17 404 | 4417 | 12 987 |
| No. of pertussis cases | |||
| Infants | 0.065 | 0.710 | −0.645 |
| Women | 0.006 | 0.001 | −0.005 |
| QALYs | |||
| Infants | 41 020.4 | 41 020.1 | 0.3 |
| Women | 31 966.0 | 31 966.0 | 0.0 |
| Total | 73 016.4 | 73 016.1 | 0.3 |
| Incremental cost per QALY gained, $* | – | – | 44 301 |
Note: QALY: quality-adjusted life-year.
↵* In 2019 Canadian dollars.